Emerson and GE Healthcare collaborate on biopharma manufacturing


Friday, 20 November, 2015

GE Healthcare’s Life Sciences business and Emerson Process Management have announced a collaboration aimed at increasing productivity and improving efficiency in the production of biopharmaceuticals such as monoclonal antibodies and vaccines.

The two companies will collaborate to integrate Emerson’s DeltaV distributed control system with GE Healthcare’s enterprise offerings and start-to-finish technologies for the global biomanufacturing industry. The first DeltaV-driven GE Healthcare installation, which is expected to be complete before the end of the year, will be a FlexFactory, GE’s integrated manufacturing platform based on single-use technologies.

GE’s start-to-finish portfolio of single-use bioprocessing technologies is said to allow manufacturers to reduce set-up times and increase manufacturing flexibility. Emerson’s DeltaV system, which uses predictive technologies to connect people, processes and production, enables remote monitoring and control from multiple locations across a company’s network. The DeltaV system will be offered as an automation control platform for GE’s single-use bioprocessing offerings.

”We believe that the combination of Emerson’s automation technologies and the GE FlexFactory will offer superior process performance, consistency of product and reduced validation time,” said Jerry Brown, senior vice president of industry solutions for Emerson Process Management. “This collaboration will support more predictable processes that eliminate unnecessary work, which translates into a reduced time to market for our customers.

“Emerson and GE share a vision that an integrated and automated approach to manufacturing has the potential to help drive improvements in production efficiency of these life-saving medicines,” added Emmanuel Ligner, global commercial manager, BioProcess, GE Healthcare Life Sciences. “This collaboration with Emerson, combined with our depth and breadth of expertise in start-to-finish technologies for bioprocessing, promises to bring real benefits to our customers and to healthcare providers worldwide.”

Related News

Microgravity causes changes in gene expression rhythms

Astronauts exposed to microgravity experience changes to physiology, including immune...

NSW, Qld announce RSV immunisation programs for infants

The government-funded programs have been designed to ensure infants and young children at the...

Gut bacteria appear important for overcoming milk allergy

Gut bacteria are thought to help reduce allergic reactions to some foods, but little is known...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd